⚠ Disclaimer: This report is generated using AI tools and is for informational purposes only. It does not constitute investment advice. Please consult a registered financial advisor before making any investment decisions.

ZYDUSWELL - Investment Analysis: Buy Signal or Bull Trap?

← Back to List

⭐ Rating: 2.3

Last Updated Time : 10 Sept 26, 05:35 am

Key Parameters

⭐ Investment Rating: 2.3

ROE1.14 %
ROCE1.69 %
PEG Ratio-34.1
Dividend Yield0.22 %
Debt to equity0.04
PAT Qtr5.50 Cr.
PAT Prev Qtr13.3 Cr.
Qtr Profit Var19.6 %
Show all parameters (20 more)
Stock CodeZYDUSWELL
Market Cap17,615 Cr.
Current Price554 ₹
High / Low612 ₹
Stock P/E392
Book Value127 ₹
Face Value2.00 ₹
DMA 50534 ₹
DMA 200493 ₹
Chg in FII Hold0.15 %
Chg in DII Hold0.26 %
RSI59.0
MACD3.99
Volume2,19,098
Avg Vol 1Wk18,13,358
Low price358 ₹
High price612 ₹
52w Index77.3 %
EPS1.21 ₹
Industry PE43.1

🏭 Industry

The nutraceuticals sector is experiencing continued expansion driven by increasing health consciousness and rising disposable incomes. However, it’s a competitive market with numerous players vying for consumer attention, making sustained growth challenging.

✅ Positive

Zydus Wellness demonstrates consistent profitability with a recent PAT increase, indicating an underlying business performing well despite the high stock valuation. The low debt-to-equity ratio (0.04) suggests financial stability and further strengthens the company's ability to withstand economic headwinds.

⚠️ Limitation

The extremely high P/E ratio of 392 relative to the industry average of 43.1 implies a significant premium valuation, making the stock vulnerable to corrections if growth expectations aren’t met consistently. Furthermore, while profitability is present, the relatively low ROE (1.14%) and ROCE (1.69%) compared to its peers suggest limited returns on invested capital, potentially restricting future growth opportunities.

📉 Company Negative News

Recent news indicates a jump in trading volumes at Zydus Wellness Ltd suggests increased investor interest, which could also increase volatility.

🧾 Long-Term Outlook

An ideal entry price zone would be between 500 ₹ and 530 ₹, acting as a buffer against short-term volatility while acknowledging the premium valuation. A holding period of 5-7 years is recommended, focusing on consistent dividend income (0.22%) alongside potential capital appreciation driven by brand expansion and market share gains in the nutraceuticals sector. Overall, this stock warrants consideration for long-term investors prioritizing durability and compounding returns over immediate price fluctuations, pending continued profitability and moderate improvements in return ratios.

Choose Technical Analysis or Fundamental Analysis above to load it.

NIFTY 50 · Investment

NEXT 50 · Investment

MIDCAP · Investment

SMALLCAP · Investment